Skip to content
Acrivastine
Semprex (acrivastine) is a small molecule pharmaceutical. Acrivastine was first approved as Semprex-d on 1994-03-25. It is used to treat allergic rhinitis perennial and urticaria in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acrivastine
+
Pseudoephedrine hydrochloride
Tradename
Company
Number
Date
Products
SEMPREX-DAuxilium PharmaceuticalsN-019806 DISCN1994-03-25
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
semprex-d2008-05-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic rhinitis perennialEFO_1001417D012221J30.89
urticariaEFO_0005531D014581L50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AX: Other antihistamines for systemic use in atc
— R06AX18: Acrivastine
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameACRIVASTINE
INNacrivastine
Description
Acrivastine is a member of the class of pyridines that is (pyridin-2-yl)acrylic acid substituted at position 6 by a [(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl group. It is a non-sedating antihistamine used for treatment of hayfever, urticaria, and rhinitis. It has a role as a H1-receptor antagonist. It is an alpha,beta-unsaturated monocarboxylic acid, a member of pyridines, a N-alkylpyrrolidine and an olefinic compound.
Classification
Small molecule
Drug classantihistaminics (histamine-H1 receptor antagonists)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1
Identifiers
PDB—
CAS-ID87848-99-5
RxCUI19959
ChEMBL IDCHEMBL1224
ChEBI ID83168
PubChem CID5284514
DrugBankDB09488
UNII IDA20F9XAI7W (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 172 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
453 adverse events reported
View more details